PPT-Atrial Fibrilation (Anticoagulation)

MA Akbarzadeh MD Assistant professor of Electrophysiology Shahid Beheshti university of medical sciences Modarres Hospital Aug 2016 New Oral Anticoagulants Practical Approach Case 1. fibrillation: diagnosis and management. د. حسين محمد جمعة . اختصاصي الامراض الباطنة . البورد العربي . كلية طب الموصل . 2010. results from a prospective study in 3755 adults.  . Enes Abdovic . Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina. Purpose. Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia . Martha Drake MS, FNP-BC. Chicago Heart and Vascular Consultants, LTD. Purdue Northwest Doctorate of Nursing Program. Learning Objectives. Discuss the incidence of atrial fibrillation (AF) in the population. Mary N. Healy, MS, ARNP-BC. Heart & Vascular Center of Sarasota. OBJECTIVES. Define the difference between paroxysmal and persistent Atrial Fibrillation. State the CVA risk per year of a 68 . yr. Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . C. atheter . Ab. lation Versus . An. tiarrhythmic Drug Therapy for . A. trial Fibrillation (CABANA) Trial . Jeanne E. Poole MD, George Johnson BSEE, Kristi H. Monahan RN, Hoss Rostami BSMSE, . Adam Silverstein MS, Hussein Al-Khalidi PhD, Mauri Wilson RN, Yves Rosenberg MD, MPH, . A ssessment of D ual antiplatelet therapy versus R ivaroxaban I n atrial F ibrillation patients T reated with left atrial appendage closure ADRIFT investigators DOI public at www.action-coeur.org www.RxFiles.ca June 2021 Drug / BRAND Vitamin K Antagonist DOACs Comments There is a positive correlation between warfarin Geoffrey Barnes, MD, MSc. University of Michigan. @. GBarnesMD. May 14, 2020. Disclosures. Grants: Pfizer/Bristol-Myers Squibb, Blue Cross Blue Shield of Michigan, NHLBI, AHRQ. Consulting: Pfizer/Bristol-Myers Squibb, Janssen, Portola, AMAG Pharmaceuticals. Clair . Huckerby. Pharmaceutical Adviser- Medicines Optimisation . Lead. Dudley CCG. Our mission. To improve the . health and wellbeing . of the . population . of . Dudley . through the . safe and effective . Figure 1 ). Management TheappropriatemanagementofAFisdependentupontheclinicalcontextinwhichitisencountered.Themajorityofcasescanbedealtwithappropriatelyonanoutpatientbasis.TheapproachtothetreatmentofA Guidelines for Clinical Care Inpatient Atrial Fibrillation Guideline TeamTeam MembersJeffrey M Rohde(Team Lead)Internal MedicineSarah E Hartley, MDInternal MedicineSarah Hanigan, PharmDPharmacy Servic - The NOAH-AFNET 6 trial -. Nina Becher, Tobias Toennis, Emanuele Bertaglia, Carina Blomstrom-Lundqvist, Nuno Cabanelas, Melanie Calvert, A John Camm, Gregory Chlouverakis, Gheorghe-Andrei Dan, Wolfgang Dichtl, Hans Christoph Diener, Alexander...